Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaMedica TherapeuticsDMAC -0.67%31 Operating Cash Flow per Share is $-0.60 as of Jun. 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,135 Biotechnology companies, DiaMedica Therapeutics ranks worse than 82.29% on this metric.
DiaMedica Therapeutics's operating cash flow per share for the
three
months ended in Jun. 2026 was $-0.15.
DiaMedica Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.60.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -12.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -0.90% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 0.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for DiaMedica Therapeutics's Operating Cash Flow per Share or its related term are showing as below:
DMAC'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -60.7 Med: 1.9 Max: 42.3
Current: -12.5
During the past 13 years, DiaMedica Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 42.30% per year. The lowest was -60.70% per year. And the median was 1.90% per year.
DMAC's 3-Year OCF Growth Rate is ranked worse than 82.29% of 1135
companies
in the Biotechnology industry
Industry Median: 17
vs DMAC: -12.50
DiaMedica Therapeutics Operating Cash Flow per Share Related Terms
DiaMedica Therapeutics Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for DiaMedica Therapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics Operating Cash Flow per Share Chart
DMAC vs SABS, AGEN, PALI: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, DiaMedica Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DiaMedica Therapeutics Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.60
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-0.60 mean?
DiaMedica Therapeutics (DMAC) has a Operating Cash Flow per Share of $-0.60 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on DiaMedica Therapeutics and its competitors. According to the industry distribution chart, DiaMedica Therapeutics ranks #934 out of 1135 companies in the Biotechnology industry, placing it in the top 82.3%.
Is DiaMedica Therapeutics' Operating Cash Flow per Share too high?
DiaMedica Therapeutics' current Operating Cash Flow per Share is $-0.60. Based on the distribution chart, DiaMedica Therapeutics ranks #934 out of 1135 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Operating Cash Flow per Share compare to SABS and AGEN?
According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #934 out of 1135 companies for Operating Cash Flow per Share. This places DiaMedica Therapeutics in the lower half of its industry. The industry median Operating Cash Flow per Share is 17.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 17.00, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on DiaMedica Therapeutics and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 17.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DiaMedica Therapeutics's current Operating Cash Flow per Share is $-0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Operating Cash Flow per Share of $-0.60. The current Operating Cash Flow per Share is $-0.60. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Operating Cash Flow per Share is $-0.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score
Get the complete analysis for DMAC
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMAC has been successfully added to your 
